Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Norway / NCT00626964
Active, not recruiting Observational

Prevention of Coronary Heart Disease in Morbidly Obese Patients

NCT00626964 · tracked via the Priya Life Science Norway tracker
Sponsor
The Hospital of Vestfold
Phase
Observational
Started
2008-02
Last updated
2025-06-11

Condition(s) studied

Morbid ObesityHypertensionType 2 DMObstructive Sleep ApneaOsteoarthrosis

Investigational drug(s) / intervention(s)

Bariatric SurgeryConservative Treatment:

Bariatric Surgery: Bariatric Surgery Treatment: Duodenal Switch, Gastric Sleeve or Gastric bypass.

Conservative Treatment:: Intensive Lifestyle Intervention Program

Study summary

The changes in risks of developing coronary heart disease in patients with morbid obesity after different weight loss interventions have not been extensively studied. The primary objective of this study is to investigate whether an intensive lifestyle intervention program in a tertiary care clinic (Spesialsykehuset for Rehabilitering) is comparable with a 7-week low-energy-diet followed by bariatric surgery in decreasing the risk of cardiovascular disease in these patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Morbidly Obese patients with BMI \> 40, or BMI \> 35 with comorbidity such as Hypertension, Obstructive Sleep Apnea, Weight Related Osteoarthrosis, Type 2 DM. Exclusion Criteria: * Participation in other weight loss program the last 12 months. Serious psychiatric conditions

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Morbid Obesity Center, Vestfold Hospital Trust Tønsberg Norway

More The Hospital of Vestfold trials in Norway

Active Surveillance Plus (AS+): High-intensity Focused Ultrasound (HIFU) in Patients With Localized Prostate Cancer Recruiting
Factors Predicting Outcome in Group Treatment of Alcohol Use Disorders (AUDs) Active, not recruiting
Impact of Body Weight and Weight Loss on Drug Bioavailability, Cardiovascular Risk Factors and Metabolic Biomarkers Active, not recruiting

Other trials for the same condition

Dietary Strategies for Remission of Type 2 Diabetes Active, not recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease Recruiting
Nesiritide in Hypertension Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT00626964 on ClinicalTrials.gov ↗ ← All trials in Norway